SAN DIEGO--(BUSINESS WIRE)--FibroGen, Inc. today announced preclinical data showing that FG-4539, a novel small molecule inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) in development for the treatment of tissue damage, improved renal function and achieved cytoprotective effects in preclinical models of acute kidney injury (AKI). The data (Abstract TH-PO1025) were presented at Renal Week 2006, the annual meeting of the American Society of Nephrology (ASN).
